Lyell Immunopharma Inc (LYEL)

NASDAQHealth CareBiotechnologySnapshot 2026-10-23

$9.39+0.11%

Close 2026-10-23 · 1-day change

Investment OutlookAs of Oct 24, 2026

What could strengthen or challenge Lyell Immunopharma Inc’s outlook?

The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.

Higher potential upsideImproving expectations

Next-FY EPS estimate change · 30 days

Comparable estimates unavailable

+10% or more+5%0%−5%−10% or less

A matching fiscal period and sufficient coverage are required.

Higher risk of downsideWeakening expectations

One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.

How this is measured

The calculation requires same-period, same-provider snapshots, positive EPS, at least five analysts and a baseline within three days of the requested lookback.

Measure / period	Management expectations	Analyst expectations
Quarter ending 2026-12-30
Revenue	—	3,400
EPS	—	-2.129
Annual ending 2026-12-31
Revenue	—	11,875
EPS	—	-7.235
Annual ending 2027-12-31
Revenue	—	13,167
EPS	—	-7.595

Management figures unavailable.

What the Thesis Depends On

Three published thesis conditions, with dated milestones shown separately.

Key Factor	Why It Matters	Current Status	Break Condition	Latest Evidence
Maintain cash sufficiency into Q3 2027	It aims to maintain cash sufficiency into Q3 2027.	Intact	Cash sufficiency falls short of meeting needs into Q3 2027	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Successful leadership transition and execution	A supporting condition in Lyell Immunopharma Inc's published investment case. The stated target is Smooth CFO transition with positive operational progress.	Improving	Leadership instability or failure to execute key milestones	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Stabilize and grow revenue beyond FY26	A primary condition in Lyell Immunopharma Inc's published investment case. The stated target is Revenue growth above -60% next year, aiming for stabilization or improvement.	Broken	Revenue decline worsens beyond -60% in FY27	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.

Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.

Incoming Evidence

Compare these dated observations with the operating requirements above

Expectations trend

Same fiscal period

FY2027 · fiscal year ending 2027-12-31 · fmp

FY2027 EPSUnavailable

$-7.99 → Unavailable · observed estimates

FY2027 revenue$0.00B

$0.01B → $0.00B · observed estimates

Exact estimates & source dates

One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.

FY2027 estimate observations · fmp
Snapshot	EPS	Revenue	EPS / revenue analysts
2026-07-24	$-7.99	$9,437,366	5 / 6
2026-07-25	$-7.99	$9,437,366	5 / 6
2026-07-26	$-7.86	$7,864,472	6 / 6
2026-07-27	$-7.86	$7,864,472	6 / 6
2026-07-28	$-7.86	$6,740,980	8 / 7
2026-07-29	$-7.86	$7,864,472	6 / 7
2026-07-30	$-7.86	$6,740,980	8 / 7
2026-07-31	$-7.86	$6,740,980	8 / 7
2026-08-01	$-7.86	$7,864,472	6 / 7
2026-08-02	$-7.86	$6,740,980	8 / 7
2026-08-03	$-7.86	$7,864,472	6 / 7
2026-08-04	$-7.86	$6,740,980	8 / 7
2026-08-05	$-7.86	$7,864,472	6 / 7
2026-08-06	$-7.86	$6,740,980	8 / 7
2026-08-07	$-7.86	$7,864,472	6 / 7
2026-08-08	Unavailable	$6,740,980	1 / 7
2026-08-09	Unavailable	$6,740,980	1 / 7
2026-08-10	$-7.86	$7,864,472	6 / 7
2026-08-12	$-7.86	$7,864,472	6 / 7
2026-08-13	$-7.86	$7,864,472	6 / 7
2026-08-14	$-7.86	$7,864,472	6 / 7
2026-08-15	Unavailable	$7,864,472	4 / 6
2026-08-16	Unavailable	$7,864,472	4 / 6
2026-08-17	Unavailable	$7,864,472	4 / 6
2026-08-18	Unavailable	$7,864,472	4 / 7
2026-08-19	Unavailable	$7,864,472	4 / 7
2026-08-20	Unavailable	$11,286	4 / 8
2026-08-21	Unavailable	$11,286	4 / 8
2026-08-22	Unavailable	$11,286	4 / 8
2026-08-23	Unavailable	$11,286	4 / 8
2026-08-24	Unavailable	$11,286	4 / 8
2026-08-25	Unavailable	$11,286	4 / 8
2026-08-26	Unavailable	$11,286	4 / 8
2026-08-27	Unavailable	$11,286	4 / 8
2026-08-28	Unavailable	$11,286	4 / 8
2026-08-29	Unavailable	$11,286	4 / 8
2026-08-30	Unavailable	$11,286	4 / 8
2026-08-31	Unavailable	$11,286	4 / 8
2026-09-01	Unavailable	$11,286	4 / 8
2026-09-02	Unavailable	$11,286	4 / 8
2026-09-03	Unavailable	$11,286	4 / 8
2026-09-04	Unavailable	$11,286	4 / 8
2026-09-05	Unavailable	$11,286	4 / 8
2026-09-06	Unavailable	$11,286	4 / 8
2026-09-07	Unavailable	$11,286	4 / 8
2026-09-08	Unavailable	$11,286	4 / 8
2026-09-09	Unavailable	$11,286	4 / 8
2026-09-10	Unavailable	$11,286	4 / 8
2026-09-11	Unavailable	$11,286	4 / 8
2026-09-12	Unavailable	$11,286	4 / 8
2026-09-13	Unavailable	$11,286	4 / 8
2026-09-14	Unavailable	$11,286	4 / 8
2026-09-15	Unavailable	$11,286	4 / 8
2026-09-16	Unavailable	$11,286	4 / 8
2026-09-17	Unavailable	$11,286	4 / 8
2026-09-18	Unavailable	$11,286	4 / 8
2026-09-19	Unavailable	$11,286	4 / 8
2026-09-20	Unavailable	$11,286	4 / 8
2026-09-21	Unavailable	$11,286	4 / 8
2026-09-22	Unavailable	$11,286	4 / 8
2026-09-23	Unavailable	$11,286	4 / 8
2026-09-24	Unavailable	$11,286	4 / 8
2026-09-25	Unavailable	$11,286	4 / 8
2026-09-26	Unavailable	$13,167	4 / 8
2026-09-27	Unavailable	$13,167	4 / 8
2026-09-28	Unavailable	$13,167	4 / 8
2026-09-29	Unavailable	$13,167	4 / 8
2026-09-30	Unavailable	$13,167	4 / 8
2026-10-01	Unavailable	$13,167	4 / 8
2026-10-02	Unavailable	$13,167	4 / 8
2026-10-03	Unavailable	$13,167	4 / 8
2026-10-04	Unavailable	$13,167	4 / 8
2026-10-05	Unavailable	$13,167	4 / 8
2026-10-06	Unavailable	$13,167	4 / 8
2026-10-07	Unavailable	$13,167	4 / 8
2026-10-08	Unavailable	$13,167	4 / 8
2026-10-09	Unavailable	$13,167	4 / 8
2026-10-10	Unavailable	$13,167	4 / 8
2026-10-11	Unavailable	$13,167	4 / 8
2026-10-12	Unavailable	$13,167	4 / 8
2026-10-13	Unavailable	$13,167	4 / 8
2026-10-14	Unavailable	$13,167	4 / 8
2026-10-15	Unavailable	$13,167	4 / 8
2026-10-16	Unavailable	$13,167	4 / 8
2026-10-17	Unavailable	$13,167	4 / 8
2026-10-18	Unavailable	$13,167	4 / 8
2026-10-19	Unavailable	$13,167	4 / 8
2026-10-20	Unavailable	$13,167	4 / 8
2026-10-21	Unavailable	$13,167	4 / 8
2026-10-22	Unavailable	$13,167	4 / 8
2026-10-23	Unavailable	$13,167	4 / 8
2026-10-24	Unavailable	$13,167	4 / 8

Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.

Compare required revenue and earnings

Analyst view

Monthly observations

Buy / Strong BuyHoldSell / Strong Sell

Exact monthly counts

Monthly rating snapshots · fmp. Missing snapshots are not zero.
Date	Buy*	Sell*
2026-05-01	5	1
2026-06-01	5	1
2026-07-01	6	1
2026-08-01	7	1
2026-09-01	7	1
2026-10-01	7	1

*Buy includes Strong Buy; Sell includes Strong Sell. Monthly counts describe the analyst mix, not the firms behind each recent action.

Latest: 7 Buy / Strong Buy · 0 Hold · 1 Sell / Strong Sell

0 upgrades0 downgrades0 maintains

Recent actions · Sep 25–Oct 24 · 0 recorded

Price-target changes

30 days

Individual price-target observations are unavailable.

0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior

How this is measured

Sep 25, 2026–Oct 24, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.

Outlook in Brief

The evidence, the remaining questions, and what comes next

What's improving

No recovery evidence is reported in the available driver assessments.

Still unresolved / key risks

Maintain cash sufficiency into Q3 2027Direct metric needs a verified mapping
Successful leadership transition and executionDirect metric needs a verified mapping
Stabilize and grow revenue beyond FY26Published status: Broken

Next proof point

Nov 11, 2026

Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.

Review earnings

Bottom line

3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.

The dated weekly assessment and its assumptions are available in Read detailed Outlook.

Historical risk context

Observed price history; separate from operating scenarios

Price sensitivity

2.9%Typical daily move · historical

Downside history

-80.5%Maximum drawdown · trailing year

Read detailed Outlook Company context, assumptions & risks

Lyell Immunopharma Inc outlook in detail

The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.

Updated Oct 24, 2026

What kind of bet this is

This is a speculative clinical-stage biotechnology company, not an established earnings compounder. The multi-year view is intact, with management on track on its lead program, but losses, elevated risk, and a limited cash runway keep the thesis fragile.

What's priced into Lyell Immunopharma Inc

The evidence flags valuation as expensive and describes the expectations gap as unjustified, though it does not provide a peer comparison. It does not indicate that the full combination of expensive valuation, weak fundamentals, and turbulence is priced in.

What the fundamentals likely do

Near term, erratic earnings and a high-miss-rate industry leave elevated risk of a miss, despite earnings beats in May and August. Over the multi-year horizon, the ronde-cel pivotal trial is on track, with pivotal data expected in mid-2027 and a planned BLA submission in the second half of 2027. Cash declined in the latest quarter, while management says it is sufficient into the third quarter of 2027.

What Lyell Immunopharma Inc hinges on

The thesis hinges on ronde-cel trial progress and whether LYEL can maintain its stated timeline through key data and regulatory milestones. Progress on LYL273 remains mixed, and a guidance cut or weaker economic data would add near-term risk; strength among healthcare bellwethers could support the sector backdrop.